Biocryst Pharmaceuticals (BCRX) EBIT (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted EBIT of -$701.6 million for Q1 2026, down 369.45% on a QoQ basis from $260.4 million in Q4 2025, and down 3405.22% year-over-year from $21.2 million in Q1 2025.
Biocryst Pharmaceuticals (BCRX) EBIT (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' EBIT history runs 17 years deep, the most recent figure standing at -$701.6 million for Q1 2026.
- Quarterly EBIT fell 3405.22% year-over-year to -$701.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$381.8 million (down 1251.08% YoY) and the FY2025 annual result came in at $341.0 million, up 13508.93% from the prior year.
- EBIT was -$701.6 million for Q1 2026 at Biocryst Pharmaceuticals, down from $260.4 million in the prior quarter.
- Across five years, EBIT topped out at $260.4 million in Q4 2025 and bottomed at -$701.6 million in Q1 2026.
- A 5-year average of -$36.2 million and a median of -$14.5 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2025 — EBIT surged 5876.06% — and 2026, when it slumped 3405.22%.
- Biocryst Pharmaceuticals' EBIT stood at -$46.3 million in 2022, then grew by 7.86% to -$42.7 million in 2023, then soared by 89.44% to -$4.5 million in 2024, then jumped by 5876.06% to $260.4 million in 2025, then slumped by 369.45% to -$701.6 million in 2026.
- Business Quant data shows BCRX's EBIT at -$701.6 million in Q1 2026, $260.4 million in Q4 2025, and $29.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.28 Bn | 2.21 Bn | 151.04 Mn | -701.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -701.60 Mn |
| Dec 31, 2025 | 260.39 Mn |
| Sep 30, 2025 | 29.59 Mn |
| Jun 30, 2025 | 29.79 Mn |
| Mar 31, 2025 | 21.23 Mn |
| Dec 31, 2024 | -4.51 Mn |
| Sep 30, 2024 | 7.69 Mn |
| Jun 30, 2024 | 8.76 Mn |
| Mar 31, 2024 | -14.49 Mn |
| Dec 31, 2023 | -42.67 Mn |
| Sep 30, 2023 | -11.92 Mn |
| Jun 30, 2023 | -20.70 Mn |
| Mar 31, 2023 | -28.42 Mn |
| Dec 31, 2022 | -46.31 Mn |
| Sep 30, 2022 | -17.45 Mn |
| Jun 30, 2022 | -34.72 Mn |
| Mar 31, 2022 | -49.96 Mn |
| Dec 31, 2021 | -52.18 Mn |
| Sep 30, 2021 | -44.58 Mn |
| Jun 30, 2021 | -29.58 Mn |